| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 127 | 2024 | 176 | 30.840 |
Why?
|
| Polymorphism, Single Nucleotide | 44 | 2022 | 459 | 7.530 |
Why?
|
| Genetic Predisposition to Disease | 45 | 2022 | 674 | 6.290 |
Why?
|
| Complement Factor H | 25 | 2020 | 146 | 4.920 |
Why?
|
| Retinal Drusen | 15 | 2022 | 16 | 4.680 |
Why?
|
| Choroidal Neovascularization | 13 | 2020 | 29 | 4.350 |
Why?
|
| Genetic Variation | 22 | 2020 | 367 | 3.490 |
Why?
|
| Geographic Atrophy | 9 | 2018 | 20 | 3.310 |
Why?
|
| Tomography, Optical Coherence | 10 | 2024 | 199 | 3.310 |
Why?
|
| Disease Progression | 33 | 2024 | 1038 | 2.850 |
Why?
|
| Genotype | 40 | 2021 | 642 | 2.820 |
Why?
|
| Proteins | 16 | 2020 | 742 | 2.770 |
Why?
|
| Risk Factors | 102 | 2023 | 4995 | 2.750 |
Why?
|
| Choroid | 7 | 2020 | 25 | 2.600 |
Why?
|
| Aged | 149 | 2024 | 13271 | 2.460 |
Why?
|
| Visual Acuity | 26 | 2024 | 111 | 2.290 |
Why?
|
| Complement Factor I | 7 | 2022 | 9 | 2.290 |
Why?
|
| Wet Macular Degeneration | 5 | 2017 | 23 | 2.190 |
Why?
|
| Smoking | 22 | 2020 | 830 | 2.030 |
Why?
|
| Aged, 80 and over | 68 | 2024 | 5060 | 1.960 |
Why?
|
| Male | 166 | 2024 | 27445 | 1.960 |
Why?
|
| Humans | 254 | 2024 | 59186 | 1.930 |
Why?
|
| Female | 169 | 2024 | 30766 | 1.880 |
Why?
|
| Phenotype | 21 | 2019 | 1154 | 1.810 |
Why?
|
| Melanoma | 53 | 2021 | 334 | 1.730 |
Why?
|
| Retinoblastoma | 18 | 2021 | 27 | 1.710 |
Why?
|
| Middle Aged | 143 | 2024 | 16208 | 1.690 |
Why?
|
| Follow-Up Studies | 50 | 2024 | 2323 | 1.680 |
Why?
|
| Complement C3 | 10 | 2020 | 61 | 1.650 |
Why?
|
| Case-Control Studies | 39 | 2021 | 1056 | 1.650 |
Why?
|
| Aging | 17 | 2020 | 722 | 1.620 |
Why?
|
| Uveal Neoplasms | 41 | 1993 | 52 | 1.620 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 8 | 2020 | 9 | 1.560 |
Why?
|
| Diet | 14 | 2024 | 635 | 1.550 |
Why?
|
| Cataract | 26 | 2016 | 54 | 1.550 |
Why?
|
| Lipase | 5 | 2011 | 47 | 1.500 |
Why?
|
| Complement System Proteins | 6 | 2021 | 126 | 1.450 |
Why?
|
| Prospective Studies | 45 | 2024 | 3093 | 1.440 |
Why?
|
| Pedigree | 15 | 2024 | 190 | 1.440 |
Why?
|
| Dog Diseases | 3 | 2021 | 54 | 1.430 |
Why?
|
| Genome-Wide Association Study | 10 | 2016 | 321 | 1.390 |
Why?
|
| Retina | 6 | 2023 | 118 | 1.380 |
Why?
|
| Fluorescein Angiography | 13 | 2024 | 51 | 1.360 |
Why?
|
| Serine Endopeptidases | 5 | 2016 | 77 | 1.300 |
Why?
|
| Dogs | 5 | 2021 | 313 | 1.270 |
Why?
|
| Retinal Vessels | 4 | 2016 | 17 | 1.230 |
Why?
|
| Twins, Monozygotic | 5 | 2014 | 69 | 1.220 |
Why?
|
| Vitamins | 8 | 2017 | 83 | 1.220 |
Why?
|
| Diet, Mediterranean | 2 | 2020 | 32 | 1.190 |
Why?
|
| Body Mass Index | 11 | 2020 | 891 | 1.180 |
Why?
|
| Risk Assessment | 11 | 2019 | 1906 | 1.150 |
Why?
|
| Antioxidants | 10 | 2016 | 243 | 1.140 |
Why?
|
| Retinal Neoplasms | 12 | 2021 | 16 | 1.100 |
Why?
|
| Fatty Acids, Omega-3 | 6 | 2024 | 48 | 1.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2020 | 201 | 1.080 |
Why?
|
| C-Reactive Protein | 4 | 2010 | 167 | 1.010 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 50 | 1.010 |
Why?
|
| Longitudinal Studies | 11 | 2024 | 1218 | 1.000 |
Why?
|
| Incidence | 30 | 2021 | 1232 | 0.990 |
Why?
|
| Vitamin D | 3 | 2017 | 149 | 0.980 |
Why?
|
| Peripherins | 1 | 2024 | 14 | 0.960 |
Why?
|
| Life Style | 5 | 2023 | 328 | 0.960 |
Why?
|
| Mutation, Missense | 4 | 2016 | 179 | 0.950 |
Why?
|
| Environment | 5 | 2015 | 125 | 0.930 |
Why?
|
| Macula Lutea | 9 | 2015 | 21 | 0.920 |
Why?
|
| Genetic Association Studies | 5 | 2024 | 120 | 0.910 |
Why?
|
| Diseases in Twins | 4 | 2011 | 54 | 0.900 |
Why?
|
| Alleles | 11 | 2020 | 425 | 0.900 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2016 | 26 | 0.880 |
Why?
|
| Cholesterol, HDL | 4 | 2012 | 78 | 0.870 |
Why?
|
| Dietary Fats | 4 | 2013 | 204 | 0.820 |
Why?
|
| Neoplasms, Second Primary | 9 | 2021 | 40 | 0.790 |
Why?
|
| Genetic Testing | 2 | 2015 | 132 | 0.780 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 72 | 0.750 |
Why?
|
| Cohort Studies | 23 | 2021 | 2434 | 0.740 |
Why?
|
| Deafness | 1 | 2021 | 33 | 0.740 |
Why?
|
| Choroid Neoplasms | 17 | 2005 | 21 | 0.710 |
Why?
|
| Ciliary Arteries | 1 | 2020 | 2 | 0.700 |
Why?
|
| Models, Genetic | 6 | 2021 | 253 | 0.690 |
Why?
|
| Prevalence | 15 | 2019 | 1278 | 0.690 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2016 | 3 | 0.680 |
Why?
|
| United States | 42 | 2021 | 7481 | 0.670 |
Why?
|
| Complement C2 | 7 | 2016 | 9 | 0.670 |
Why?
|
| Vision Disorders | 4 | 2018 | 58 | 0.670 |
Why?
|
| Survivors | 11 | 2019 | 148 | 0.660 |
Why?
|
| Lutein | 6 | 2024 | 24 | 0.660 |
Why?
|
| Apolipoproteins E | 5 | 2012 | 99 | 0.660 |
Why?
|
| Gene Frequency | 10 | 2015 | 131 | 0.660 |
Why?
|
| Eye Proteins | 5 | 2018 | 73 | 0.640 |
Why?
|
| Biomarkers | 5 | 2017 | 1203 | 0.640 |
Why?
|
| Complement C9 | 2 | 2021 | 4 | 0.640 |
Why?
|
| Haplotypes | 7 | 2011 | 117 | 0.640 |
Why?
|
| Blindness | 3 | 2015 | 37 | 0.630 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2017 | 78 | 0.620 |
Why?
|
| ATP-Binding Cassette Transporters | 3 | 2011 | 37 | 0.610 |
Why?
|
| Chromosome Mapping | 6 | 2016 | 293 | 0.600 |
Why?
|
| Collagen Type VIII | 2 | 2016 | 2 | 0.590 |
Why?
|
| Complement Factor B | 6 | 2016 | 11 | 0.590 |
Why?
|
| Prognosis | 19 | 2021 | 1564 | 0.590 |
Why?
|
| Zinc | 6 | 2008 | 88 | 0.580 |
Why?
|
| Awards and Prizes | 1 | 2017 | 30 | 0.580 |
Why?
|
| Ophthalmology | 1 | 2017 | 23 | 0.580 |
Why?
|
| Algorithms | 6 | 2023 | 986 | 0.570 |
Why?
|
| Macrophages | 2 | 2020 | 1003 | 0.570 |
Why?
|
| Eye Diseases | 4 | 2013 | 37 | 0.570 |
Why?
|
| DNA | 2 | 2024 | 787 | 0.560 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 50 | 0.560 |
Why?
|
| Adult | 80 | 2024 | 15707 | 0.560 |
Why?
|
| Cataract Extraction | 15 | 2009 | 35 | 0.560 |
Why?
|
| Bruch Membrane | 1 | 2016 | 5 | 0.550 |
Why?
|
| Chymotrypsin | 1 | 2016 | 28 | 0.550 |
Why?
|
| Epigenomics | 2 | 2014 | 54 | 0.540 |
Why?
|
| Zinc Compounds | 1 | 2016 | 7 | 0.540 |
Why?
|
| Fibrinogen | 2 | 2022 | 38 | 0.540 |
Why?
|
| Heterozygote | 7 | 2022 | 168 | 0.530 |
Why?
|
| Vitamin B Complex | 1 | 2016 | 22 | 0.530 |
Why?
|
| Homocysteine | 2 | 2006 | 57 | 0.520 |
Why?
|
| Aspirin | 5 | 2013 | 186 | 0.520 |
Why?
|
| Folic Acid | 1 | 2016 | 58 | 0.510 |
Why?
|
| Fish Products | 2 | 2006 | 6 | 0.500 |
Why?
|
| Lod Score | 4 | 2014 | 26 | 0.490 |
Why?
|
| Cancer Survivors | 3 | 2021 | 80 | 0.490 |
Why?
|
| Inflammation | 2 | 2020 | 1100 | 0.490 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 208 | 0.480 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 1446 | 0.470 |
Why?
|
| Proportional Hazards Models | 12 | 2013 | 672 | 0.460 |
Why?
|
| Risk | 15 | 2014 | 370 | 0.460 |
Why?
|
| Exome | 1 | 2014 | 72 | 0.460 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2014 | 47 | 0.450 |
Why?
|
| Women's Health | 4 | 2016 | 390 | 0.450 |
Why?
|
| Polymorphism, Genetic | 4 | 2009 | 197 | 0.450 |
Why?
|
| Multivariate Analysis | 12 | 2014 | 926 | 0.450 |
Why?
|
| Diet Records | 7 | 2017 | 47 | 0.450 |
Why?
|
| Odds Ratio | 10 | 2015 | 772 | 0.450 |
Why?
|
| Dietary Supplements | 8 | 2017 | 246 | 0.440 |
Why?
|
| Environmental Exposure | 2 | 2013 | 204 | 0.440 |
Why?
|
| Amino Acid Substitution | 4 | 2016 | 253 | 0.430 |
Why?
|
| Mutation | 7 | 2024 | 2422 | 0.430 |
Why?
|
| Optic Atrophy | 1 | 2013 | 6 | 0.430 |
Why?
|
| Genetic Linkage | 4 | 2009 | 101 | 0.430 |
Why?
|
| Complement Pathway, Alternative | 2 | 2011 | 27 | 0.430 |
Why?
|
| Myopia | 1 | 2012 | 2 | 0.420 |
Why?
|
| Complement C1 | 1 | 2012 | 4 | 0.410 |
Why?
|
| Twins, Dizygotic | 3 | 2011 | 54 | 0.410 |
Why?
|
| Models, Biological | 4 | 2018 | 1137 | 0.400 |
Why?
|
| Markov Chains | 1 | 2012 | 36 | 0.400 |
Why?
|
| Age of Onset | 4 | 2020 | 173 | 0.400 |
Why?
|
| Fundus Oculi | 9 | 2016 | 17 | 0.400 |
Why?
|
| Protons | 19 | 1993 | 60 | 0.390 |
Why?
|
| Models, Theoretical | 2 | 2013 | 257 | 0.390 |
Why?
|
| Minerals | 2 | 2007 | 19 | 0.390 |
Why?
|
| Demography | 3 | 2023 | 178 | 0.390 |
Why?
|
| Penetrance | 1 | 2011 | 11 | 0.390 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 4 | 2020 | 5 | 0.390 |
Why?
|
| Photography | 9 | 2020 | 43 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 202 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 5 | 2019 | 25 | 0.390 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2011 | 42 | 0.390 |
Why?
|
| Optic Disk Drusen | 1 | 2011 | 1 | 0.390 |
Why?
|
| Collagen Type X | 1 | 2011 | 4 | 0.380 |
Why?
|
| Betaine | 1 | 2011 | 10 | 0.380 |
Why?
|
| DNA Mutational Analysis | 4 | 2024 | 195 | 0.380 |
Why?
|
| Methionine | 1 | 2011 | 56 | 0.370 |
Why?
|
| Albuminuria | 1 | 2011 | 23 | 0.370 |
Why?
|
| Rhipicephalus | 1 | 2010 | 1 | 0.360 |
Why?
|
| Acaricides | 1 | 2010 | 1 | 0.360 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 113 | 0.360 |
Why?
|
| Pyrethrins | 1 | 2010 | 5 | 0.360 |
Why?
|
| Retrospective Studies | 17 | 2016 | 5959 | 0.360 |
Why?
|
| Sodium Channels | 1 | 2010 | 20 | 0.360 |
Why?
|
| Survival Analysis | 5 | 2016 | 553 | 0.350 |
Why?
|
| Drug Resistance | 1 | 2010 | 97 | 0.340 |
Why?
|
| Kidney Diseases | 1 | 2011 | 157 | 0.330 |
Why?
|
| Surveys and Questionnaires | 18 | 2011 | 2577 | 0.330 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 275 | 0.330 |
Why?
|
| Skin Neoplasms | 6 | 2021 | 403 | 0.330 |
Why?
|
| Adolescent | 31 | 2024 | 5912 | 0.320 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2009 | 67 | 0.320 |
Why?
|
| Biological Evolution | 1 | 2009 | 109 | 0.320 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2009 | 179 | 0.320 |
Why?
|
| Animals | 17 | 2021 | 19559 | 0.310 |
Why?
|
| Time Factors | 15 | 2016 | 3561 | 0.310 |
Why?
|
| Breeding | 2 | 2021 | 26 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 4 | 2013 | 394 | 0.310 |
Why?
|
| Point Mutation | 3 | 2010 | 162 | 0.310 |
Why?
|
| Australia | 2 | 2021 | 93 | 0.300 |
Why?
|
| DNA Methylation | 3 | 2014 | 273 | 0.300 |
Why?
|
| Eye Neoplasms | 8 | 2014 | 17 | 0.300 |
Why?
|
| Complement C3b | 2 | 2020 | 20 | 0.300 |
Why?
|
| Health Behavior | 1 | 2011 | 473 | 0.290 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1128 | 0.290 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 846 | 0.290 |
Why?
|
| Reproducibility of Results | 10 | 2016 | 1544 | 0.290 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2007 | 86 | 0.290 |
Why?
|
| Sarcoma | 4 | 2019 | 34 | 0.290 |
Why?
|
| Siblings | 4 | 2012 | 45 | 0.280 |
Why?
|
| Vegetables | 2 | 2024 | 91 | 0.280 |
Why?
|
| Cross-Sectional Studies | 7 | 2016 | 2460 | 0.280 |
Why?
|
| Ranibizumab | 2 | 2017 | 20 | 0.270 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2006 | 17 | 0.270 |
Why?
|
| Carotenoids | 8 | 2007 | 72 | 0.270 |
Why?
|
| TRPP Cation Channels | 1 | 2006 | 24 | 0.270 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2017 | 27 | 0.270 |
Why?
|
| Intravitreal Injections | 2 | 2017 | 47 | 0.270 |
Why?
|
| Models, Statistical | 5 | 2012 | 306 | 0.270 |
Why?
|
| Energy Intake | 6 | 2017 | 213 | 0.260 |
Why?
|
| Linkage Disequilibrium | 3 | 2011 | 49 | 0.260 |
Why?
|
| Radiotherapy | 6 | 2019 | 63 | 0.260 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2006 | 14 | 0.260 |
Why?
|
| Young Adult | 8 | 2024 | 4314 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 3 | 2019 | 498 | 0.260 |
Why?
|
| Hypertension | 2 | 2011 | 598 | 0.250 |
Why?
|
| Feeding Behavior | 7 | 2008 | 314 | 0.250 |
Why?
|
| Genome, Human | 2 | 2005 | 218 | 0.250 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 1092 | 0.250 |
Why?
|
| Diabetes Mellitus | 2 | 2009 | 532 | 0.240 |
Why?
|
| Wolves | 1 | 2004 | 3 | 0.240 |
Why?
|
| Retinal Dystrophies | 1 | 2024 | 4 | 0.240 |
Why?
|
| Genetic Drift | 1 | 2004 | 15 | 0.240 |
Why?
|
| Genes, MHC Class II | 1 | 2004 | 36 | 0.240 |
Why?
|
| Chromosomes, Human | 1 | 2005 | 53 | 0.240 |
Why?
|
| Genetics, Population | 1 | 2004 | 41 | 0.240 |
Why?
|
| Alcohol Drinking | 6 | 2000 | 298 | 0.230 |
Why?
|
| Activities of Daily Living | 6 | 2000 | 298 | 0.230 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1534 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 675 | 0.230 |
Why?
|
| Child | 14 | 2024 | 4296 | 0.230 |
Why?
|
| Multimodal Imaging | 1 | 2024 | 67 | 0.230 |
Why?
|
| Nuts | 1 | 2003 | 7 | 0.230 |
Why?
|
| Interleukin-6 | 1 | 2005 | 309 | 0.220 |
Why?
|
| Body Constitution | 1 | 2003 | 15 | 0.220 |
Why?
|
| Nutritional Status | 1 | 2024 | 118 | 0.220 |
Why?
|
| United Kingdom | 2 | 2021 | 69 | 0.220 |
Why?
|
| Registries | 6 | 2011 | 801 | 0.220 |
Why?
|
| Glaucoma | 5 | 2016 | 48 | 0.210 |
Why?
|
| Ciliary Body | 7 | 2000 | 11 | 0.210 |
Why?
|
| Reproductive History | 1 | 2002 | 15 | 0.210 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2002 | 18 | 0.210 |
Why?
|
| Area Under Curve | 2 | 2013 | 128 | 0.210 |
Why?
|
| Dietary Fats, Unsaturated | 3 | 2008 | 23 | 0.210 |
Why?
|
| Fovea Centralis | 3 | 1996 | 17 | 0.200 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2022 | 22 | 0.200 |
Why?
|
| Postmenopause | 2 | 2006 | 246 | 0.200 |
Why?
|
| Cardiovascular Diseases | 6 | 2007 | 827 | 0.200 |
Why?
|
| Logistic Models | 6 | 2014 | 1252 | 0.200 |
Why?
|
| Lipids | 3 | 2010 | 305 | 0.200 |
Why?
|
| Tissue Donors | 2 | 2020 | 132 | 0.190 |
Why?
|
| Vitamin A | 5 | 2007 | 27 | 0.190 |
Why?
|
| Microscopy, Confocal | 2 | 2020 | 219 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2014 | 248 | 0.190 |
Why?
|
| Ultraviolet Rays | 3 | 2000 | 122 | 0.190 |
Why?
|
| Radiation Injuries | 7 | 2009 | 55 | 0.190 |
Why?
|
| Machine Learning | 1 | 2023 | 135 | 0.190 |
Why?
|
| Double-Blind Method | 6 | 2016 | 684 | 0.190 |
Why?
|
| Infant | 12 | 2019 | 1526 | 0.180 |
Why?
|
| Rehabilitation | 1 | 2000 | 6 | 0.180 |
Why?
|
| Vision, Low | 1 | 2000 | 9 | 0.180 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 7 | 0.180 |
Why?
|
| Genetic Markers | 3 | 2012 | 121 | 0.180 |
Why?
|
| HSP110 Heat-Shock Proteins | 1 | 2020 | 1 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 1 | 2000 | 34 | 0.180 |
Why?
|
| Plant Lectins | 1 | 2020 | 6 | 0.170 |
Why?
|
| Age Factors | 15 | 2019 | 1518 | 0.170 |
Why?
|
| Molecular Epidemiology | 2 | 2010 | 26 | 0.170 |
Why?
|
| Survival Rate | 9 | 2021 | 787 | 0.170 |
Why?
|
| Staining and Labeling | 3 | 2020 | 123 | 0.170 |
Why?
|
| Geriatric Assessment | 3 | 2015 | 161 | 0.170 |
Why?
|
| Obesity | 3 | 2007 | 1189 | 0.160 |
Why?
|
| Child, Preschool | 11 | 2019 | 1835 | 0.160 |
Why?
|
| Intraocular Pressure | 3 | 2005 | 61 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 117 | 0.160 |
Why?
|
| Retinal Diseases | 4 | 1994 | 30 | 0.160 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 171 | 0.160 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2008 | 80 | 0.160 |
Why?
|
| Health Surveys | 1 | 1999 | 306 | 0.150 |
Why?
|
| Ascorbic Acid | 5 | 2007 | 52 | 0.150 |
Why?
|
| Public Health | 2 | 2003 | 180 | 0.150 |
Why?
|
| Vitamin E | 5 | 2007 | 55 | 0.150 |
Why?
|
| Pigment Epithelium of Eye | 6 | 2009 | 12 | 0.150 |
Why?
|
| Sequence Alignment | 2 | 2010 | 290 | 0.140 |
Why?
|
| Collagen Type IV | 1 | 2016 | 3 | 0.140 |
Why?
|
| Base Sequence | 2 | 2013 | 1308 | 0.140 |
Why?
|
| Nurses | 3 | 2016 | 103 | 0.140 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 1024 | 0.140 |
Why?
|
| Riboflavin | 2 | 2016 | 14 | 0.140 |
Why?
|
| False Positive Reactions | 2 | 2013 | 74 | 0.130 |
Why?
|
| Choroid Diseases | 1 | 2016 | 4 | 0.130 |
Why?
|
| Mastocytosis, Systemic | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cell Degranulation | 1 | 2016 | 20 | 0.130 |
Why?
|
| Thiamine | 1 | 2016 | 19 | 0.130 |
Why?
|
| Microsatellite Repeats | 2 | 2006 | 37 | 0.130 |
Why?
|
| Regional Blood Flow | 1 | 2016 | 107 | 0.130 |
Why?
|
| Mast Cells | 1 | 2016 | 41 | 0.130 |
Why?
|
| Quality of Life | 3 | 2008 | 1108 | 0.130 |
Why?
|
| Autoantigens | 1 | 2016 | 125 | 0.130 |
Why?
|
| Retinal Degeneration | 1 | 2016 | 30 | 0.130 |
Why?
|
| Bevacizumab | 1 | 2015 | 56 | 0.130 |
Why?
|
| Regression Analysis | 11 | 2010 | 482 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 759 | 0.120 |
Why?
|
| Retinoblastoma Protein | 2 | 2012 | 36 | 0.120 |
Why?
|
| Equipment Design | 1 | 2016 | 314 | 0.120 |
Why?
|
| Germ-Line Mutation | 2 | 2012 | 47 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 1996 | 138 | 0.120 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2014 | 8 | 0.120 |
Why?
|
| Neuroglia | 1 | 2015 | 79 | 0.120 |
Why?
|
| Population Surveillance | 3 | 2019 | 205 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2020 | 764 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2009 | 454 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 105 | 0.120 |
Why?
|
| Gliosis | 1 | 2014 | 27 | 0.120 |
Why?
|
| Retinal Vein | 2 | 1998 | 5 | 0.120 |
Why?
|
| Bestrophins | 3 | 2003 | 3 | 0.120 |
Why?
|
| Disease | 1 | 2014 | 26 | 0.120 |
Why?
|
| Eye Enucleation | 7 | 1993 | 11 | 0.120 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 1971 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 63 | 0.120 |
Why?
|
| Leiomyosarcoma | 2 | 2011 | 9 | 0.110 |
Why?
|
| Brachytherapy | 3 | 2009 | 40 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 1990 | 291 | 0.110 |
Why?
|
| Optic Disk | 3 | 1993 | 24 | 0.110 |
Why?
|
| Chloride Channels | 3 | 2003 | 27 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1994 | 39 | 0.110 |
Why?
|
| Triglycerides | 2 | 2010 | 242 | 0.110 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 14 | 0.110 |
Why?
|
| Eating | 3 | 2007 | 139 | 0.110 |
Why?
|
| Complement Activation | 1 | 2013 | 53 | 0.110 |
Why?
|
| Retinal Artery | 1 | 1993 | 2 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 291 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2015 | 371 | 0.110 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 16 | 0.110 |
Why?
|
| Electrooculography | 2 | 2003 | 5 | 0.110 |
Why?
|
| Nuclear Family | 2 | 2003 | 19 | 0.110 |
Why?
|
| Cobalt Radioisotopes | 4 | 2009 | 5 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2013 | 106 | 0.100 |
Why?
|
| Nutrition Surveys | 2 | 2011 | 152 | 0.100 |
Why?
|
| Massachusetts | 7 | 2002 | 2082 | 0.100 |
Why?
|
| Eye Color | 2 | 2000 | 3 | 0.100 |
Why?
|
| Kinetics | 1 | 2014 | 731 | 0.100 |
Why?
|
| Skin | 2 | 1992 | 350 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2015 | 5134 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 60 | 0.100 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2011 | 10 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 30 | 0.100 |
Why?
|
| Protein Conformation | 1 | 2014 | 761 | 0.090 |
Why?
|
| Behavior | 1 | 2011 | 38 | 0.090 |
Why?
|
| Anthropometry | 1 | 2011 | 80 | 0.090 |
Why?
|
| Observer Variation | 3 | 2006 | 201 | 0.090 |
Why?
|
| Mass Screening | 3 | 2008 | 639 | 0.090 |
Why?
|
| Iris | 1 | 1990 | 3 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1991 | 66 | 0.090 |
Why?
|
| Classification | 1 | 1990 | 12 | 0.090 |
Why?
|
| Medical Errors | 1 | 2012 | 193 | 0.090 |
Why?
|
| Complement C3b Inactivator Proteins | 1 | 2010 | 4 | 0.090 |
Why?
|
| Family | 2 | 2009 | 219 | 0.090 |
Why?
|
| Boston | 2 | 2011 | 329 | 0.090 |
Why?
|
| Radiotherapy Dosage | 5 | 2000 | 79 | 0.090 |
Why?
|
| Introns | 2 | 2008 | 106 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 36 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2010 | 72 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2014 | 1114 | 0.090 |
Why?
|
| Liver Neoplasms | 6 | 1992 | 274 | 0.090 |
Why?
|
| Macular Edema | 1 | 2010 | 24 | 0.090 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2009 | 3 | 0.090 |
Why?
|
| Exons | 2 | 2008 | 193 | 0.090 |
Why?
|
| Lens, Crystalline | 1 | 2009 | 15 | 0.090 |
Why?
|
| Cattle | 1 | 2010 | 306 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 433 | 0.080 |
Why?
|
| Protein Binding | 1 | 2014 | 1542 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2009 | 59 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 1 | 2009 | 87 | 0.080 |
Why?
|
| Leukocytes | 1 | 2009 | 107 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2007 | 839 | 0.080 |
Why?
|
| Sclera | 1 | 1989 | 11 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 1993 | 11 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2010 | 297 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 522 | 0.080 |
Why?
|
| Seafood | 1 | 2008 | 18 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 16 | 0.080 |
Why?
|
| Eyeglasses | 1 | 2008 | 7 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 22 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 453 | 0.080 |
Why?
|
| ROC Curve | 1 | 2008 | 259 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2009 | 254 | 0.070 |
Why?
|
| Eyelid Neoplasms | 3 | 1986 | 9 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1576 | 0.070 |
Why?
|
| Epidemiologic Methods | 2 | 1999 | 68 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 6 | 1992 | 104 | 0.070 |
Why?
|
| Laser Therapy | 2 | 1997 | 36 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cell Count | 2 | 2016 | 128 | 0.070 |
Why?
|
| Calcium Channels | 1 | 2006 | 95 | 0.070 |
Why?
|
| Ultrasonics | 1 | 1986 | 16 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 130 | 0.070 |
Why?
|
| Cryptorchidism | 1 | 1985 | 9 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2019 | 1310 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 403 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2005 | 10 | 0.060 |
Why?
|
| Lipoprotein(a) | 1 | 2005 | 8 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 15 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2005 | 17 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2005 | 24 | 0.060 |
Why?
|
| Progesterone | 1 | 2006 | 157 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2005 | 30 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 52 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1124 | 0.060 |
Why?
|
| Eye Injuries | 3 | 1991 | 14 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 236 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 322 | 0.060 |
Why?
|
| Skull Neoplasms | 1 | 1985 | 7 | 0.060 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2004 | 4 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2014 | 29 | 0.060 |
Why?
|
| Founder Effect | 1 | 2004 | 11 | 0.060 |
Why?
|
| Population Dynamics | 1 | 2004 | 18 | 0.060 |
Why?
|
| Physicians | 4 | 1994 | 433 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 200 | 0.060 |
Why?
|
| Glycemic Index | 1 | 2004 | 25 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 456 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2004 | 76 | 0.060 |
Why?
|
| Species Specificity | 1 | 2004 | 336 | 0.060 |
Why?
|
| Cricetinae | 4 | 2021 | 376 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 1 | 2004 | 87 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2004 | 103 | 0.050 |
Why?
|
| Fruit | 1 | 2004 | 121 | 0.050 |
Why?
|
| Light Coagulation | 3 | 1996 | 5 | 0.050 |
Why?
|
| Diet Surveys | 4 | 2008 | 77 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 261 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 208 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1982 | 7 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 112 | 0.050 |
Why?
|
| Conjunctival Neoplasms | 1 | 1982 | 1 | 0.050 |
Why?
|
| Data Collection | 3 | 1994 | 384 | 0.050 |
Why?
|
| Plasmacytoma | 1 | 1982 | 9 | 0.050 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 1988 | 9 | 0.050 |
Why?
|
| Retinal Detachment | 4 | 1990 | 17 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 1982 | 124 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2014 | 51 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 1992 | 301 | 0.050 |
Why?
|
| Contact Lenses, Extended-Wear | 3 | 1991 | 3 | 0.050 |
Why?
|
| Contact Lenses, Hydrophilic | 3 | 1991 | 6 | 0.050 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2001 | 17 | 0.050 |
Why?
|
| Linoleic Acid | 1 | 2001 | 17 | 0.050 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2021 | 5 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 1985 | 300 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2001 | 33 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2021 | 103 | 0.050 |
Why?
|
| Hemolysis | 1 | 2021 | 38 | 0.050 |
Why?
|
| Polymerization | 1 | 2021 | 35 | 0.050 |
Why?
|
| alpha-Linolenic Acid | 1 | 2001 | 5 | 0.050 |
Why?
|
| Cricetulus | 1 | 2021 | 102 | 0.050 |
Why?
|
| beta Carotene | 5 | 2003 | 67 | 0.050 |
Why?
|
| Sheep | 1 | 2021 | 166 | 0.050 |
Why?
|
| CHO Cells | 1 | 2021 | 191 | 0.050 |
Why?
|
| Optometry | 1 | 2000 | 8 | 0.050 |
Why?
|
| Diabetes Complications | 4 | 2007 | 102 | 0.050 |
Why?
|
| Occupational Therapy | 1 | 2000 | 12 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2003 | 283 | 0.040 |
Why?
|
| Health Status | 3 | 1999 | 449 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 2000 | 73 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 1981 | 188 | 0.040 |
Why?
|
| Twin Studies as Topic | 1 | 1999 | 15 | 0.040 |
Why?
|
| Health Personnel | 2 | 2001 | 340 | 0.040 |
Why?
|
| Keratitis | 2 | 1989 | 9 | 0.040 |
Why?
|
| Eye | 3 | 1989 | 54 | 0.040 |
Why?
|
| New England | 5 | 1991 | 267 | 0.040 |
Why?
|
| Radiotherapy, High-Energy | 3 | 1989 | 8 | 0.040 |
Why?
|
| Retinal Perforations | 1 | 1999 | 7 | 0.040 |
Why?
|
| Zeaxanthins | 3 | 2007 | 16 | 0.040 |
Why?
|
| Xanthophylls | 3 | 2007 | 24 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 161 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 226 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 1991 | 195 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 1999 | 138 | 0.040 |
Why?
|
| Retinal Vein Occlusion | 1 | 1998 | 18 | 0.040 |
Why?
|
| Sex Factors | 5 | 2011 | 959 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2000 | 542 | 0.040 |
Why?
|
| Health Services Research | 1 | 1999 | 270 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 1997 | 23 | 0.040 |
Why?
|
| Research | 1 | 1999 | 191 | 0.040 |
Why?
|
| Ethanol | 1 | 2000 | 306 | 0.040 |
Why?
|
| Corneal Ulcer | 3 | 1991 | 3 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 36 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2002 | 531 | 0.030 |
Why?
|
| Vision Screening | 2 | 1993 | 8 | 0.030 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2016 | 13 | 0.030 |
Why?
|
| Epithelium | 2 | 1987 | 96 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2015 | 51 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 2 | 2008 | 30 | 0.030 |
Why?
|
| Statistics as Topic | 3 | 1997 | 147 | 0.030 |
Why?
|
| Triethylenemelamine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2009 | 120 | 0.030 |
Why?
|
| Astrocytes | 1 | 2015 | 114 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 28 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 2014 | 4 | 0.030 |
Why?
|
| Self Disclosure | 1 | 1994 | 37 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 14 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 59 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 134 | 0.030 |
Why?
|
| Cyclotrons | 1 | 1993 | 3 | 0.030 |
Why?
|
| Fatty Acids | 2 | 2001 | 194 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1996 | 275 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 1993 | 25 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 1993 | 18 | 0.030 |
Why?
|
| Biopsy | 2 | 1992 | 373 | 0.030 |
Why?
|
| Random Allocation | 2 | 1991 | 198 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 1990 | 115 | 0.030 |
Why?
|
| Fibrosis | 1 | 1993 | 151 | 0.030 |
Why?
|
| Uveitis | 1 | 1993 | 29 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 1991 | 196 | 0.030 |
Why?
|
| Accidental Falls | 2 | 1993 | 144 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 77 | 0.030 |
Why?
|
| Postal Service | 1 | 1992 | 6 | 0.030 |
Why?
|
| Maryland | 1 | 2012 | 32 | 0.020 |
Why?
|
| Complement Factor D | 1 | 2011 | 4 | 0.020 |
Why?
|
| Hand | 1 | 1992 | 65 | 0.020 |
Why?
|
| Actuarial Analysis | 3 | 1988 | 16 | 0.020 |
Why?
|
| Cell Nucleolus | 3 | 1987 | 68 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 60 | 0.020 |
Why?
|
| Genomics | 1 | 2014 | 313 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 1993 | 217 | 0.020 |
Why?
|
| Exudates and Transudates | 2 | 1988 | 11 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 1991 | 12 | 0.020 |
Why?
|
| Aphakia, Postcataract | 1 | 1991 | 1 | 0.020 |
Why?
|
| Contact Lenses | 1 | 1991 | 1 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 72 | 0.020 |
Why?
|
| Quality Control | 1 | 1991 | 70 | 0.020 |
Why?
|
| Altitude | 1 | 1990 | 14 | 0.020 |
Why?
|
| Postoperative Care | 2 | 2008 | 112 | 0.020 |
Why?
|
| Sunlight | 1 | 1990 | 29 | 0.020 |
Why?
|
| Personality | 1 | 1990 | 25 | 0.020 |
Why?
|
| Particle Accelerators | 2 | 1989 | 6 | 0.020 |
Why?
|
| Longevity | 1 | 2011 | 111 | 0.020 |
Why?
|
| Radon | 1 | 2009 | 2 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2009 | 16 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 1989 | 5 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 42 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 1992 | 303 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1994 | 421 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 51 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1989 | 233 | 0.020 |
Why?
|
| Compliance | 1 | 1989 | 5 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1990 | 576 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 1991 | 781 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1991 | 807 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 2030 | 0.020 |
Why?
|
| Linear Models | 2 | 2004 | 419 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 17 | 0.020 |
Why?
|
| Atrophy | 1 | 2008 | 64 | 0.020 |
Why?
|
| Phosphorus | 1 | 1988 | 17 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1988 | 35 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 1990 | 483 | 0.020 |
Why?
|
| Lipid Bilayers | 1 | 1988 | 49 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 98 | 0.020 |
Why?
|
| Developing Countries | 1 | 2008 | 81 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 2 | 1989 | 61 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 200 | 0.020 |
Why?
|
| Liposomes | 1 | 1988 | 98 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 664 | 0.020 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1987 | 7 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 168 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 61 | 0.020 |
Why?
|
| SEER Program | 1 | 2007 | 63 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2007 | 54 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 77 | 0.020 |
Why?
|
| Visual Fields | 2 | 2000 | 42 | 0.020 |
Why?
|
| Helium | 1 | 1986 | 7 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 1986 | 12 | 0.020 |
Why?
|
| Cryosurgery | 1 | 1986 | 23 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1989 | 636 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 1985 | 19 | 0.020 |
Why?
|
| Estrogens | 1 | 2006 | 113 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1985 | 23 | 0.020 |
Why?
|
| Urology | 1 | 1985 | 25 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1987 | 165 | 0.020 |
Why?
|
| Energy Transfer | 1 | 1985 | 9 | 0.020 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1985 | 9 | 0.020 |
Why?
|
| Chondrosarcoma | 1 | 1985 | 6 | 0.020 |
Why?
|
| Chordoma | 1 | 1985 | 6 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 2005 | 17 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1985 | 137 | 0.010 |
Why?
|
| Glioma | 1 | 1985 | 101 | 0.010 |
Why?
|
| Hepatectomy | 1 | 1984 | 59 | 0.010 |
Why?
|
| Irritants | 1 | 1983 | 5 | 0.010 |
Why?
|
| Family Practice | 1 | 1985 | 204 | 0.010 |
Why?
|
| Neoplasms | 2 | 1992 | 1226 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 398 | 0.010 |
Why?
|
| Confidence Intervals | 2 | 1994 | 256 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2003 | 125 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 2 | 1993 | 104 | 0.010 |
Why?
|
| Pediatrics | 1 | 1985 | 266 | 0.010 |
Why?
|
| Orbital Neoplasms | 1 | 1982 | 6 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2001 | 28 | 0.010 |
Why?
|
| Palliative Care | 1 | 1984 | 202 | 0.010 |
Why?
|
| Pregnancy | 2 | 1993 | 2352 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 291 | 0.010 |
Why?
|
| Fishes | 1 | 2001 | 23 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2000 | 19 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 1454 | 0.010 |
Why?
|
| Microsomes | 1 | 2000 | 10 | 0.010 |
Why?
|
| Tobacco Use Disorder | 1 | 1983 | 244 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2000 | 31 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 436 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 2000 | 64 | 0.010 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2000 | 49 | 0.010 |
Why?
|
| Glycosylation | 1 | 2000 | 134 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2000 | 178 | 0.010 |
Why?
|
| Brassica | 1 | 1999 | 7 | 0.010 |
Why?
|
| Spinacia oleracea | 1 | 1999 | 11 | 0.010 |
Why?
|
| Light | 1 | 2000 | 201 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 134 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1999 | 14 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 443 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1981 | 519 | 0.010 |
Why?
|
| Ion Channels | 1 | 1999 | 86 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1985 | 721 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 1997 | 28 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1997 | 114 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 1904 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2097 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 1992 | 1127 | 0.010 |
Why?
|
| Mesocricetus | 2 | 1985 | 93 | 0.010 |
Why?
|
| Vision, Ocular | 1 | 1995 | 18 | 0.010 |
Why?
|
| Lenses, Intraocular | 1 | 1994 | 4 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 40 | 0.010 |
Why?
|
| Distance Perception | 1 | 1992 | 2 | 0.010 |
Why?
|
| Occupations | 1 | 1993 | 52 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1992 | 85 | 0.010 |
Why?
|
| Telephone | 1 | 1992 | 121 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1994 | 249 | 0.010 |
Why?
|
| Educational Status | 1 | 1993 | 271 | 0.010 |
Why?
|
| Necrosis | 1 | 1992 | 137 | 0.010 |
Why?
|
| Automobile Driving | 1 | 1992 | 55 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1991 | 12 | 0.010 |
Why?
|
| Craniocerebral Trauma | 1 | 1991 | 58 | 0.010 |
Why?
|
| Selection Bias | 1 | 1990 | 24 | 0.010 |
Why?
|
| Mitosis | 1 | 1992 | 207 | 0.010 |
Why?
|
| Psychometrics | 1 | 1992 | 354 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 1991 | 71 | 0.010 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1991 | 106 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 1991 | 150 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1993 | 291 | 0.010 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1989 | 8 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1991 | 99 | 0.010 |
Why?
|
| Alcoholism | 1 | 1993 | 306 | 0.010 |
Why?
|
| Glaucoma, Neovascular | 1 | 1989 | 2 | 0.010 |
Why?
|
| Hygiene | 1 | 1989 | 11 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1993 | 731 | 0.010 |
Why?
|
| Comorbidity | 1 | 1993 | 1084 | 0.010 |
Why?
|
| Remission Induction | 1 | 1989 | 137 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1988 | 18 | 0.000 |
Why?
|
| Palmitic Acids | 1 | 1988 | 3 | 0.000 |
Why?
|
| Myristic Acids | 1 | 1988 | 5 | 0.000 |
Why?
|
| Myristic Acid | 1 | 1988 | 9 | 0.000 |
Why?
|
| Stearic Acids | 1 | 1988 | 8 | 0.000 |
Why?
|
| Palmitic Acid | 1 | 1988 | 13 | 0.000 |
Why?
|
| Spectrophotometry | 1 | 1988 | 31 | 0.000 |
Why?
|
| Electrochemistry | 1 | 1988 | 27 | 0.000 |
Why?
|
| Hyphema | 1 | 1988 | 3 | 0.000 |
Why?
|
| Chemistry | 1 | 1988 | 30 | 0.000 |
Why?
|
| Eye Foreign Bodies | 1 | 1988 | 8 | 0.000 |
Why?
|
| Probability | 1 | 1988 | 172 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1988 | 89 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 93 | 0.000 |
Why?
|
| Colloids | 1 | 1988 | 49 | 0.000 |
Why?
|
| Pigmentation | 1 | 1988 | 25 | 0.000 |
Why?
|
| Retinal Hemorrhage | 1 | 1987 | 8 | 0.000 |
Why?
|
| Sodium | 1 | 1987 | 59 | 0.000 |
Why?
|
| Iris Diseases | 1 | 1987 | 2 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1989 | 449 | 0.000 |
Why?
|
| Risk-Taking | 1 | 1988 | 159 | 0.000 |
Why?
|
| Athletic Injuries | 1 | 1988 | 70 | 0.000 |
Why?
|
| Temperature | 1 | 1988 | 300 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 427 | 0.000 |
Why?
|
| Ultrasonic Therapy | 1 | 1985 | 6 | 0.000 |
Why?
|
| Carbon Tetrachloride | 1 | 1985 | 9 | 0.000 |
Why?
|
| Occupational Diseases | 1 | 1988 | 264 | 0.000 |
Why?
|
| Hematoxylin | 1 | 1985 | 11 | 0.000 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1985 | 12 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1985 | 157 | 0.000 |
Why?
|
| Mice | 1 | 1999 | 10237 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 473 | 0.000 |
Why?
|
| Computers | 1 | 1985 | 48 | 0.000 |
Why?
|
| Methods | 1 | 1985 | 39 | 0.000 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1985 | 41 | 0.000 |
Why?
|
| Rabbits | 1 | 1985 | 330 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1985 | 241 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1985 | 349 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1985 | 174 | 0.000 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1982 | 1 | 0.000 |
Why?
|
| Dermoid Cyst | 1 | 1982 | 3 | 0.000 |
Why?
|
| Epidermal Cyst | 1 | 1982 | 10 | 0.000 |
Why?
|
| Fibroma | 1 | 1982 | 12 | 0.000 |
Why?
|
| Hemangioma | 1 | 1982 | 27 | 0.000 |
Why?
|
| China | 1 | 1982 | 141 | 0.000 |
Why?
|
| Carcinoma | 1 | 1982 | 116 | 0.000 |
Why?
|